Asarina Pharma has recently completed a share issue for listing on Nasdaq First North. The share issue raised SEK 142.8M before issue costs. Provided that the over-allotment option of up to 350,000 shares is fully exercised, the Company will receive a total of SEK 150.2M before issue costs. Following the share issue, Asarina Pharma will have around 1,200 shareholders.
Nasdaq’s review of Asarina Pharma has now been completed and the Company’s application for admission to trading on Nasdaq First North is approved. Nasdaq’s approval is conditional upon that the Company fulfills customary terms. The shares will be traded under the ticker ASAP and ISIN code SE0011641794. For further information, refer to the prospectus that has been prepared in connection with the share issue and application for listing. The prospectus is available on Asarina Pharma’s website, www.asarinapharma.com.
Erik Penser Bank AB is the Company’s Certified Adviser and has been the financial adviser in connection with the share issue and the listing. Fredersen Advokatbyrå has been the legal adviser in connection with the share issue and the listing.